Impact Biomedical shares surge 83.76% premarket after SEC filing discloses merger amendments with Dr Ashleys.

Impact Biomedical Inc. (IBO) surged 83.76% in premarket trading following a Securities and Exchange Commission filing disclosing amendments to its pending merger with Dr. Ashleys Bio Labs Limited. The company revised the Merger and Share Exchange Agreement, extending the deal’s deadline to July 1, 2026, and adjusting share allocations to grant Dr. Ashleys’ sole shareholder 94.20% ownership post-closing. The amendments also clarified obligations with DSS, Inc., including additional share issuances tied to funding commitments. These updates, disclosed on February 27, 2026, signaled progress in finalizing the merger, bolstering investor confidence in the transaction’s viability. The stock closed regular trading up 0.80% at $0.41 before surging further in after-hours trading to $0.77, reflecting optimism over the revised terms and extended timeline, which may reduce uncertainty for stakeholders.